A Phase I, Escalating Dose Study of VB6-845, a Recombinant Fusion Protein Targeting EpCAM, in Patients With Advanced Solid Tumours of Epithelial Origin

Trial Profile

A Phase I, Escalating Dose Study of VB6-845, a Recombinant Fusion Protein Targeting EpCAM, in Patients With Advanced Solid Tumours of Epithelial Origin

Discontinued
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2016

At a glance

  • Drugs VB 6845 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Viventia Biotechnologies
  • Most Recent Events

    • 09 Apr 2008 Status changed from recruiting to discontinued, as reported in ClinicalTrials.gov.
    • 29 Jan 2008 Twelve patients have been enrolled to date.
    • 25 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top